{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": {
    "pdf_name": "CDC_Influenza_vaccines",
    "source_pdf": "data/clinical_files/CDC Influenza vaccines.pdf",
    "total_pages": 2,
    "total_blocks": 20,
    "total_characters": 2329
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 1,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "Flublok Quadrivalent (Sanofi Pasteur) 0.5 mL PFS \u226518 yrs 45 \u00b5g/0.5 mL IM ... RIV4 (recombinant HA vaccine)",
      "relevance_explanation": "This quote identifies Flublok Quadrivalent as a recombinant HA vaccine, which is relevant because recombinant technology is the focus of the claim. It establishes the presence of a recombinant vaccine in the document, which is necessary context for discussing its immune response characteristics."
    }
  ],
  "model_used": "gpt-4.1"
}